Categories
Health

Covid-19 Vaccines: Dr. B Web site Will Match You With Leftover Doses

In the rush of getting an elusive vaccine appointment, the leftover dose has become the stuff of the pandemic.

Additional footage to be used within hours of leaving the cold store has been distributed to drugstore customers buying midnight snacks, people who are nurse friends, and people who show up at certain grocery stores and pharmacies at closing time. At some major vaccination sites, the race to use each dose triggers a series of phone calls at the end of the day.

In either case, if the remaining dose cannot find an available arm, it must go to the trash.

Now a New York-based start-up wants to put the rush for leftover cans in order. Dr. B, as the company is called, compares vaccine providers who are receiving additional vaccines with people who are willing to receive them right away.

Since the service began last month, more than 500,000 people have submitted a variety of personal information to sign up for the service, which is free and free for providers too. Two vaccination centers have started testing the program, and the company said about 200 other providers had applied to participate.

Dr. B is just an attempt to coordinate the chaotic patchwork of public and private websites that allow eligible people to find vaccine appointments. Critics said the current system is confusing, unreliable, and often requires access to the Internet and time to search for websites for the infrequent appointment. In many places, people who are not yet eligible for a shot are also largely ignored, missing the opportunity to put them on a formal waiting list.

While Dr. B does not solve all of these broader problems, if it increases the hope that it will, it could serve as a model for better and fairer vaccination planning.

“I think this is a great idea,” said Sharon Whisenand, the administrator for the Randolph County’s Department of Health in rural Missouri.

Ms. Whisenand said 60 to 80 people did not show up for the county’s first mass vaccination event in late January, prompting her staff to make dozens of calls to people on a waiting list at the end of the day. “We sounded a bit like a call center,” she said. The workers eventually found enough buyers to give most of the extra doses, but some shots were thrown away.

Dr. B is a not-for-profit organization founded as a not-for-profit company whose mission is to ensure the efficient and fair distribution of vaccines. But its founder, Cyrus Massoumi, a tech entrepreneur, took Dr. B not yet described. He said he is funding the project out of pocket and has no plans to generate any income. The company is named after his grandfather, nicknamed Dr. Bubba wore and became a doctor during the 1918 pandemic influenza.

Mr. Massoumi is the founder and former CEO of ZocDoc, which helps patients find available doctor appointments, and the founder of Shadow, a company that uses technology and on-site volunteers to bring lost pets together with their owners. Like these two efforts, Dr. B, to make connections between groups who need something from each other.

“Ultimately, patients need this vaccine, and there are providers who need help getting it to the priority people,” Massoumi said in an interview. “That’s my motivation.”

After Mr Massoumi came up with the idea for Dr. B, he recruited several engineers from Haven, a now-defunct healthcare collaboration between Amazon, Berkshire Hathaway and JP Morgan, to build the website and underlying database. Amazon has also donated web services, Massoumi said.

The half a million people who signed up for the service entered basic biographical information such as date of birth, address, underlying health conditions, and the type of work they did. When vaccine providers near you receive additional doses, they will be notified by SMS and have 15 minutes to respond. Then they have to be ready to travel quickly to the vaccination site.

The company’s database sorts people according to local vaccine priority rules, so providers have a better chance of delivering their leftover shots to those most in need.

For many vendors, this proper practice would be a welcome change from the random systems they currently use. At some pharmacies and supermarket chains, workers have combed the aisles to find people ready to get vaccinated at the last minute. Elsewhere, vaccine hopefuls wait in line at the end of each shift, which could pose a risk of infection, especially for the most vulnerable.

Despite some grumbling about younger, healthier people skipping the line by snapping leftover cans, public health experts and many ethicists say the most important thing is that the vaccines don’t go to waste. At the start of the vaccine rollout, some politicians like New York Governor Andrew M. Cuomo threatened sanctions against providers for failing to follow the priority rules exactly, and a doctor in Texas lost his job after giving leaked doses to people with illness including his wife.

For those offered a last minute vaccine, “that person shouldn’t say no because they want it to go to someone else,” said Dr. Shikha Jain, assistant professor of medicine at the University of Illinois, Chicago, and a contributor -founder of IMPACT, a group that worked to improve the fair distribution of vaccines. “However, it’s really important to be deliberate and fair,” she said.

Mr Massoumi said he took several steps to make sure the service was fair. This included turning down early media inquiries from mainstream publications and instead using Dr. B on Zoom calls with representatives from groups such as black churches and Native American community groups, as the pandemic has disproportionately affected non-white groups.

Updated

March 9, 2021, 11:16 p.m. ET

“It was really important to him to put these communities at the top or get the information early,” said Brooke Williams, Black and a member of the Resistance Revival Chorus in New York. She joined one of the early Zoom calls and started spreading the word.

“To hear about gunshots being thrown away was just heartbreaking and annoying,” she said.

However, the service suffers from some of the same obstacles that have hampered vaccination efforts so far. While signing in is easy, it requires an internet connection as well as instant access to a mobile phone. Due to the last minute nature of the leftover cans, attendees need flexible schedules and access to transportation.

“It’s still heavily dependent on the Internet, so it depends on who’s hearing about it,” said Arthur Caplan, a medical ethicist at New York University’s Grossman School of Medicine. “It seems like he’s trying to solve a problem and do something good, but I’m sad that governments – counties, cities, national organizations – didn’t prepare for it and then didn’t respond faster to advice and To give instructions. “

Mr. Massoumi noted that the website allowed people such as community volunteers to sign up on behalf of others. The site is also available in Spanish.

He noted that the setup of the program, which allows users to log in and then wait for a notification in order of priority, is better than other sites that require hours of website updating when there is a chance they are lucky to achieve a rare opening.

What you need to know about the vaccine rollout

Some local health authorities, including Washington, DC and West Virginia, are moving to a similar pre-registration system that can help level the playing field.

“It feels like you don’t know where you are and the only way to save your spot is to update a browser,” said John Brownstein, a researcher at Boston Children’s Hospital, who runs VaccineFinder.org , an online portal that helps people book vaccine appointments.

For Brittany Marsh, who owns a pharmacy in Little Rock, Ark., Figuring out what to do with leftover cans has been a daily problem.

She said the number of no-shows had increased as vaccines became more available and others had to cancel at the last minute because they developed Covid-19 or were exposed to someone who did. Although sometimes people call, she said, “More than once we just have a no-show.”

Ms. Marsh has been testing Dr. B. and said this saved her staff the hassle of calling a waiting list from other customers to quickly fill the open spaces. With Dr. B she said, “I know they at least call what we think is the right group of people to get these shots so we never have to waste any.”

Dr. B only disclosed a few details about which providers have expressed interest in using its platform. Apart from the fact that the providers are based in 30 states and include doctors’ offices, pharmacies, and medical departments of large academic institutions.

The company collects sensitive personal information, which it promises to strictly protect, even though the data is not protected by the federal health privacy law known as HIPAA, as the company is not itself a medical service provider.

When asked about his long-term plans for the company, Mr Massoumi declined, noting that the vaccination race was not going to end anytime soon.

“Right now we just want the vaccines to be allocated in the best possible way,” he said. “I can’t think of a better way of spending money on solving the pandemic. So we’re just bowing our heads and focusing on it.”

Categories
World News

Alaska Is First State to Supply Vaccines to All Residents 16 and Over

Anyone 16 or older who live or work in Alaska is now eligible for the vaccine, Governor Mike Dunleavy said Tuesday evening. This makes it the first state to grant all residents access to the vaccine.

Alaska has 16 percent of its population fully vaccinated, the highest in the country, according to a New York Times database.

“If Alaskans had any questions about vaccine eligibility and criteria, I hope today’s announcement clears that up for you,” said Adam Crum, commissioner for the state Department of Health. “Simply put, you are eligible to receive the vaccine.”

Mr Dunleavy encouraged all “Alaskans who are considering” to get vaccinated, adding that the vaccine “now gives us an opportunity in Alaska to outperform other states.”

The Alaska announcement came as other states are rapidly expanding access to vaccines. New York and Minnesota announced Tuesday that they would allow large swaths of their populations to do so.

The pace of vaccination in the United States has continued to accelerate. About 2.15 million doses are administered daily, according to a New York Times database. The Centers for Disease Control and Prevention announced Tuesday that about 61.1 million people had received at least one dose of a Covid-19 vaccine, including about 32.1 million people completely using Johnson’s single-dose vaccine & Johnson or the two-dose vaccination series from Pfizer-BioNTech and Moderna.

Some parts of Alaska have reached 90 percent vaccination rates among seniors, the governor said in a statement. In the Nome Census Area, over 60 percent of residents aged 16 and over received at least one shot.

“We want to get our economy up and running again. We want to get our society up and running again, ”said Dunleavy. “We want to leave this virus behind us – as far as possible, as quickly as possible.”

The Pfizer vaccine is available to people aged 16 and over in Alaska, while Johnson & Johnson and Moderna vaccines are available to people aged 18 years and over.

New York Governor Andrew M. Cuomo said Tuesday that his state would lower the age threshold for Covid-19 vaccine approval starting Wednesday so that anyone over the age of 60 can be vaccinated.

New York State will also open vaccination ratings next week for large numbers of publicly available workers, including government employees, nonprofits and essential building services workers. These people can start vaccinating on March 17th.

New York will join a handful of other US states in allowing vaccinations for anyone over 60. The majority have set their minimum age for admission to 65 years.

During a performance in Syracuse, Mr. Cuomo pointed to the expected increase in the offer of the federal government as a reason for the expansion of the vaccine authorization.

Workers who can be vaccinated next week include civil servants, social workers and social workers, government inspectors, plumbing workers, election workers, Department of Motor Vehicles and county clerks.

According to Cuomo, appointments for people over 60 will be opened from Wednesday at 8 a.m. People over 65 were able to qualify for a vaccine in January.

Elsewhere, Minnesota Governor Tim Walz announced Tuesday that the state would extend eligibility to more than 1.8 million Minnesotans this week, including key workers in industries such as food services and public transportation, and those 45 and older with at least one underlying medical condition . The announcement is “weeks ahead of schedule,” the governor said in a statement, as the state aims to meet its goal of vaccinating 70 percent of Minnesotans 65 and older this week.

Ohio residents aged 50 and over and people with certain conditions that were not yet eligible can get a vaccine this week, Governor Mike DeWine announced on Monday.

Categories
Health

Charts present how vaccines are working

Pharmacist Murtaza Abdulkarim (L) administers a dose of the AstraZeneca / Oxford Covid-19 vaccine to a patient at the Al-Abbas Islamic Center in Birmingham, West Midlands on February 4, 2021 at a temporary vaccination center manned by pharmacists and pharmacist assistants.

Oli Scarff | AFP | Getty Images

LONDON – The first real data from the UK vaccination program has given some insight into the effectiveness of vaccines against Covid-19.

Developed by Pfizer and BioNTech, the vaccine was the first vaccine to be approved and launched in the UK in December. Those over 80, health workers and nursing home staff were the first to be vaccinated. This was soon followed by the shot developed by the Briton AstraZeneca and the University of Oxford.

Here are four charts summarizing how effective these vaccines are and how they are doing their part in fighting the pandemic:

Falling deaths in those over 85

Since older people were the first to be vaccinated from December 8th, it is noticeable that deaths from Covid are falling the fastest in these age groups. The graph below shows deaths from Covid in Scotland, with a decline in the over-85 group as the vaccination program gained momentum. Click here for the full details.

An increase in antibodies

A blood test published last week by Imperial College London found that nearly 14% of the UK population now have antibodies to the coronavirus. While this does not necessarily mean immunity, the results of the people vaccinated and the level of their antibody levels were interesting. 18,000 participants in the 155,000-person study were vaccinated and the results are shown in the table below. Click here for the full details.

A separate study in England found that the highest percentage of people who tested positive for antibodies was aged 80 and over, at 41%, which, according to statisticians, “is most likely due to the high vaccination rate in this group”.

The real effectiveness of the Pfizer shot

Public Health England has done a thorough study of how effective the Pfizer BioNTech vaccine has been in protecting against symptomatic disease. The table below shows that a dose is 57% effective against symptomatic Covid-19 disease in people over 80 years of age (from 28 days after the first dose).

The effectiveness of the vaccine is calculated using a mathematical statistic called the odds ratio. Click here for full data and methods.

… and the AstraZeneca vaccine

Public Health Scotland also collected data on the AstraZeneca-Oxford vaccine for all ages. The graph shows that the Pfizer BioNTech and Oxford AstraZeneca vaccines reduce the risk of Covid-19 hospitalization by up to 85% and 94%, respectively, in the fourth week after receiving a first dose. Click here for the dates and the full methodology.

Since the start of the vaccination rollout, the UK has targeted all four key priority groups. The goal is now to vaccinate all over 50s by mid-April and all adults by the end of July, two months ahead of an earlier goal.

As of Sunday, over 20 million people had received their first vaccine dose and nearly 800,000 had received both doses, government data said.

The UK vaccination program was widely hailed as a triumph amid tragedy. The UK has the fifth highest number of infections in the world after the US, India, Brazil and Russia with over 4.1 million registered infections and 123,083 deaths. This is the fifth highest number of deaths in the world, according to Johns Hopkins University.

—CNBC’s Bryn Bache contributed to this article.

Categories
Health

All three Covid vaccines extremely efficient, urges individuals to take obtainable shot

Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, speaks during a press conference at the White House in the James Brady Press Briefing Room of the White House on January 21, 2021 in Washington, DC.

Alex Wong | Getty Images

The Chief Medical Officer of the White House, Dr. Anthony Fauci said Sunday he would be taking the newly approved Johnson & Johnson Covid-19 vaccine and urged Americans to take the available shot if they are eligible.

The Food and Drug Administration on Saturday approved J & J’s vaccine, giving the US a third tool to fight the pandemic after vaccines from Moderna and Pfizer. The company expects to ship 20 million cans by the end of March.

“All three of them are really pretty good, and people should go for the one that is best available to them,” Fauci said on NBC’s Meet the Press.

“If you go to a place and have J&J, and that’s the one that’s available now, I’d take it,” Fauci said. “Personally, I would do the same. I think people need to be vaccinated as soon and as quickly as possible.”

The J&J vaccine is different from the others in that it is a single dose and patients do not have to return for a second dose. It can be stored at refrigerator temperature for months. The shot has shown an overall effectiveness of 66%, 72% in the USA and 57% in South Africa, where variant B.1.351 has spread rapidly.

Although the Pfizer and Moderna vaccines showed higher efficacy rates in two-dose studies compared to J & J’s single-dose vaccine, Fauci insisted that the J&J shot isn’t a weaker vaccine, and the trial data shouldn’t be for the three Shots are compared as they were tested at different times.

“You must now have three highly effective vaccines,” said Fauci. “There is no doubt about that.”

As the country sees a decline in new coronavirus cases and an improvement in vaccination rates, Fauci warned states to relax restrictions on pandemics prematurely, which could lead to a renewed spike in infections.

Cases have dropped from 300,000 a day to around 70,000, a baseline that’s still too high, Fauci said.

“We don’t want to keep preventing people from doing what they want. But let’s get to a good level,” Fauci told CBS ‘Face the Nation. “Let’s vaccinate a lot more people. And then you could withdraw these kinds of public health measures.”

“But right now that we are going under and reaching a plateau, it is not time to declare victory because we are not yet victorious,” he said.

Categories
Business

Covid Vaccines: Johnson & Johnson’s shot licensed by F.D.A.

WASHINGTON – The Food and Drug Administration on Saturday approved Johnson & Johnson’s one-of-a-kind emergency Covid-19 vaccine, starting millions of doses of a third effective vaccine that could hit Americans early next week.

The announcement came at a critical time as the sharp drop in coronavirus cases appears to have plateaued and millions of Americans are on waiting lists to be shot.

Johnson & Johnson has pledged to make 100 million cans available to the US by the end of June. Combined with the 600 million doses of two-shot vaccines manufactured by Pfizer-BioNTech and Moderna due to arrive in late July, there will be more than enough shots to cover any American adult who wants one.

But federal and state health officials are concerned that some people may view Johnson & Johnson’s shot as an inferior option despite poor data.

The 72 percent effectiveness of the new vaccine at the clinical trial site in the US – as a number of scientists have celebrated – is below the rate of around 95 percent found in trials testing the Moderna and Pfizer-BioNTech vaccines. Across all trial sites, the Johnson & Johnson vaccine showed 85 percent effectiveness against severe forms of Covid-19 and 100 percent effectiveness against hospitalizations and deaths.

“Don’t necessarily get involved in the numbers game because it’s a really good vaccine and we need as many good vaccines as possible,” said Dr. Anthony S. Fauci, the government’s leading infectious disease expert, in an interview on Saturday. “Instead of analyzing the difference between 94 and 72, accept the fact that you now have three highly effective vaccines. Period.”

If the Johnson & Johnson vaccine had been the first to be approved in the US instead of the third, “everyone would be doing handstands and backflips and high-fives,” said Dr. James T. McDeavitt, Dean of Clinical Affairs, Baylor College of Medicine.

On Sunday, a committee of vaccine experts advising the Centers for Disease Control and Prevention will meet to discuss whether certain populations should be prioritized for the vaccine. These guidelines have been eagerly awaited by state health authorities in anticipation of FDA approval.

A administration official familiar with the distribution of the vaccine said deliveries would start Monday and deliveries could arrive as early as Tuesday.

Johnson & Johnson has announced that it will ship nearly four million cans once the FDA clears distribution and another 16 million cans by the end of March. That’s far less than the 37 million cans foreseen in his $ 1 billion federal contract, but the contract states that deliveries 30 days late are still considered to be on time.

The federal government is paying the company $ 10 per dose for a total of 100 million doses that should be ready by the end of June, significantly less per dose than agreed to pay Moderna and Pfizer, who developed their vaccine with a German partner, BioNTech .

With Johnson & Johnson’s single-dose vaccine, states can rapidly increase the number of people fully vaccinated. Unlike the other two vaccines, it can be stored at standard refrigeration temperatures for at least three months.

Dr. Danny Avula, the vaccine coordinator for Virginia, said supplies from Johnson & Johnson would add nearly a fifth to the state’s vaccine allotment next week.

“I’m super excited,” he said. “One hundred percent effectiveness against deaths and hospitalizations? That’s all I need to hear “

He said the state is planning mass vaccination events specifically for the Johnson & Johnson vaccine, in part to suppress suspicions that it is a lesser product targeted at specific groups.

“It will be very clear that this is Johnson & Johnson. Here’s what you need to know about it. If you want to do this, come in with your eyes open, ”he said. “If not, keep your place on the list.”

Michele Roberts, assistant secretary for the Washington State Department of Health, said it was difficult to explain the technical aspects of the differences between Johnson & Johnson’s vaccine studies and those of other drug companies. Because the studies were conducted at different times and with different protocols, accurate comparisons can be problematic. All three studies showed that the vaccines offer strong protection against Covid-19, especially in severe illness.

Updated

Apr. 27, 2021, 6:11 p.m. ET

Understanding the subtle contrasts requires a lot of “scientific expertise,” she said. “There are so many different factors at play. But that’s not quick public news. “

Even some clinicians misinterpret the differences between the Covid-19 vaccines, health officials said. “They assume it’s apples to apples, but it’s apples to oranges, or worse, apples to ripening,” said Dr. Nirav Shah, the director of the Maine Center for Disease Control and Prevention.

Last week, said Dr. Shah, the head of a group of specialist clinics in his state initially turned down his offer to ship doses of the Johnson & Johnson vaccine, saying his doctors were concerned that this would be less effective than the other two.

He said he said to him, “Stop right there. We now need to have a Zoom talk with all of your medical staff. “Instead, he carefully explained the results from Johnson & Johnson to the vendor, who then spoke to their employees. Twenty minutes later the provider sent him a message: “We are on board. Send us the J & J. ”

Some state officials have been frustrated with what they see as the lack of a coordinated plan by the Biden government to introduce the new vaccine. The governors have sought advice from the White House, but government officials have so far left it to the states to decide.

Although Johnson & Johnson received ample federal support and agreed to manufacture at risk, federal officials familiar with the way it worked said the company had an overly conservative approach to manufacturing and emphasized scaling at the back of its contract.

As a result, Johnson & Johnson is expected to ship the majority of its 100 million cans in late spring or early summer. The country will continue to need them: by the end of May, Pfizer and Moderna have promised to ship enough doses to vaccinate 200 million Americans, so that around 60 million eligible adults are not yet covered. However, with more contagious variants of the virus spreading, health officials are keen to vaccinate as many Americans as possible as soon as possible.

Johnson & Johnson produced its first batch of approximately four million cans at its Dutch facility, federal officials said. The company’s new facility in Baltimore is expected to supply the majority of its cans for the United States.

Americans are becoming more open to Covid-19 vaccines, according to the latest survey by the Kaiser Family Foundation, which has been overseeing attitudes since December. Fifty-five percent of adults say they either received a dose or will receive it as soon as possible, up from 34 percent in December.

However, Rupali Limaye, who studies vaccine hesitation at Johns Hopkins University, said she was concerned about whether health officials and community leaders would emphasize the strengths of the Johnson & Johnson vaccine, including how well it did the occurrence of Severe Covid-19, hospitalization and hospitalization prevents death.

“People will want to know: why is this so much less and what does it mean to us?” She said. “I worry that there will be more questions than trust.”

Without further instructions from the federal government, the state health authorities consult with each other as to where the new source of supply should be directed.

Dr. Marcus Plescia, the chief medical officer of the Association of State and Territorial Health Authorities, which represents state health authorities, predicted that “many states will be a little careful” about where they originally ship the vaccine.

“They don’t mean to say, ‘OK, we’re going to use this vaccine for our rural population because it’s easier to ship.'” This can spark a backlash from people who, for some reason, mistakenly suspect a second-rate vaccine is being offered , he said.

Dr. Maine-based Shah said the new vaccine is particularly good for drive-through vaccination sites, also because it is less likely to cause the kind of side effects that need to be monitored. Health officials in other states also said it might make sense to target the doses at transient populations who are less likely to show up in second shots. Universities could be particularly interested.

Dr. Jennifer Dillaha, the state epidemiologist with the Arkansas Health Department, said the simpler storage conditions for the vaccine could also increase the number of vaccinations in other non-medical facilities such as senior centers or locations in underserved communities with no pharmacies or health care providers.

To limit possible confusion, some state health officials said they plan to initially route the new vaccine to new locations, not those who are already administering the other vaccines.

Dr. Shah said some Maine pharmacists would prefer to treat one type of Covid-19 vaccine at a time. Although that can change, said Dr. Shah: “Every day is important. Anything that is introduced into the workflow that slows the rate of vaccination hurts us. “

Carl Zimmer contributed to the reporting.

Categories
Health

Future Vaccines Rely upon Take a look at Topics in Quick Provide: Monkeys

Mark Lewis was dying to find monkeys. Millions of lives around the world were at stake.

Mr. Lewis, the CEO of Bioqual, was responsible for providing laboratory monkeys to pharmaceutical companies such as Moderna and Johnson & Johnson, which the animals needed to develop their Covid-19 vaccines. But when the coronavirus spread in the United States last year, there were few of the specially bred monkeys in the world.

About a dozen companies that could not provide scientists with monkeys, which can cost more than $ 10,000 each, looked for laboratory animals at the height of the pandemic.

“We lost our jobs because we couldn’t take care of the animals on time,” said Lewis.

The world needs monkeys whose DNA is very similar to that of humans to develop Covid-19 vaccines. However, a global shortage stemming from unexpected demand due to the pandemic has been exacerbated by a recent ban on the sale of wild animals from China, the leading supplier of laboratory animals.

The recent shortage has rekindled discussion of creating a strategic monkey reserve in the United States, an emergency supply similar to that maintained by the government for oil and grain.

As new variants of the coronavirus threaten to obsolete the current amount of vaccines, scientists are looking for new monkey sources, and the US is rethinking its reliance on China, a rival with its own biotech ambitions.

The pandemic has underscored the extent to which China controls the supplies of life-saving items, including masks and drugs, that the United States needs during a crisis.

American scientists have searched private and government-funded facilities in Southeast Asia and Mauritius, a tiny island nation off Southeast Africa, for populations of their preferred test subjects, rhesus and cynomolgus monkeys, also known as long-tailed macaques.

But no country can make amends for what China delivered before. Before the pandemic, China supplied over 60 percent of the 33,818 primates, mostly cynomolgus macaques, imported to the United States in 2019, according to analyst estimates based on data from the Centers for Disease Control and Prevention.

In the United States, 25,000 laboratory monkeys live in its seven primate centers – predominantly rhesus monkeys with pink faces. About 600 to 800 of these animals have undergone coronavirus research since the pandemic began.

Scientists say monkeys are ideal samples for coronavirus vaccine research before testing in humans. The primates share more than 90 percent of our DNA. Because of their similar biology, they can be tested with nasal swabs and their lungs scanned. Scientists say finding a replacement for testing Covid-19 vaccines is almost impossible, despite drugs like dexamethasone, the steroid used to treat President Donald J. Trump, have been tested in hamsters.

The United States once relied on India to supply rhesus monkeys. In 1978 India stopped exporting after the Indian press reported that the monkeys were being used in the US for military tests. Pharmaceutical companies were looking for an alternative.

Eventually they landed on China.

The pandemic disrupted the decades-long relationship between American scientists and Chinese suppliers.

“When the Chinese market closed everyone was forced to go to fewer animals available,” said Lewis.

Updated

Apr. 23, 2021, 7:02 p.m. ET

For years, several airlines, including the major American airlines, have also refused to transport animals used in medical research because animal rights activists oppose it.

Meanwhile, the price of a cynomolgus monkey has more than doubled year over year to well over $ 10,000, Lewis said. Scientists researching cures for other diseases, including Alzheimer’s and AIDS, say their work has been delayed as coronavirus researchers give priority to the animals.

The shortage has led more and more American scientists to urge the government to ensure constant care for the animals.

Skip Bohm, associate director and senior veterinarian at the Tulane National Primate Research Center outside of New Orleans, The discussion about a strategic monkey sanctuary began about 10 years ago under the directors of the national primate research centers. However, due to the time and money invested in setting up a breeding program, a supply was never created.

“Our idea was like the strategic oil reserve in that there is a lot of fuel somewhere that can only be tapped in an emergency,” said Professor Bohm.

However, when new variants of the virus are discovered that may resume the race for a vaccine, scientists say the government must take immediate action on the supply.

“The strategic monkey reserve is exactly what we needed to deal with Covid and we just didn’t have it,” said Keith Reeves, principal researcher at the Center for Virology and Vaccine Research at Harvard Medical School.

However, a robust strategic reserve may still not be able to meet the skyrocketing demand for laboratory animals, researchers in China have learned. Even with a government-controlled supply of around 45,000 monkeys, researchers in China say they are struggling with a shortage.

Researchers often collect hundreds of samples from a single monkey, whose tissue can be frozen for years and examined over long periods of time. Scientists say they make the most of every animal, but monkeys infected with Covid-19 cannot be returned to live among other healthy animals and will eventually have to be euthanized.

In January, Shen Weiguo, general manager of Shanghai Technology Venture Capital Group, told local lawmakers that three major biomedical companies in the city were nearly 2,750 research monkeys, according to a report in the state news media last year. The deficit is set to grow 15 percent annually for the next five years, Shen said.

Hubei Topgene Biotechnology breeds monkeys for its own research and for export. The US used to be the top export destination, but the company currently doesn’t have enough animals to conduct its own experiments, said Yan Shuo, a sales manager.

“Now it’s not even about money,” said Mr. Yan. “We don’t even have monkeys to sell abroad.”

The United States has seven national primate research centers where the animals, when unexplored, live in colonies with access to nature and enrichment activities. The facilities are attached to research universities and are funded by the National Institutes of Health. Animal rights activists have long accused the centers of abuse, including separating babies from their mothers.

Matthew R. Bailey, president of the National Association for Biomedical Research, said he was preparing to increase the monkey shortage in the Biden administration. He said China’s decision to stop exports at the start of the pandemic was “likely a prudent emergency,” but suggested that China could resume exports given how the virus is now spreading.

The Chinese Ministry of Foreign Affairs said the ban was not aimed at specific species or countries.

As soon as the international situation improves and the conditions for imports and exports are met, the Ministry will issue a statement actively considering resuming import and export permits and other related work.

Experts said the United States had some responsibility for not having enough research monkeys.

Budgets in the national primate centers have either remained flat or have been falling for more than a decade. Koen Van Rompay, an infectious disease expert at the California National Primate Research Center, said the federal government asked the center to expand its breeding colonies about 10 years ago but did not grant it an increase in funding, so it instead downsized its colony.

“What we did in a number of cases was give birth control to our women,” said Dr. Van Rompay. “So fewer babies would be born in the spring.”

At a panel organized by the National Institutes of Health in December 2018, the scientists discussed the challenges facing American primate care. There was an awareness then that “if China chooses to turn the cone off, we will be in big trouble,” said Jeffrey Roberts, associate director of the California National Primate Research Center.

Participants “agreed that the need to breed cynomolgus macaques domestically is essential and, if not met, could jeopardize biomedical research in the United States as a whole,” a report from the meeting said. “They stressed that it may be too late to meet these needs, but it will certainly be too late within a few months.”

Amber Wang and Elsie Chen contributed to the research.

Categories
Health

UK PM Boris Johnson pronounces 100-day goal to develop new vaccines

UK Prime Minister Boris Johnson speaks during a press conference on Coronavirus (COVID-19) on Downing Street on January 15, 2021 in London, England.

Dominic Lipinski | Getty Images

LONDON – UK Prime Minister Boris Johnson will call on the leaders of the world’s largest economies to support efforts to accelerate the development of new vaccines.

Johnson, who will chair a virtual meeting with G-7 leaders on Friday, is expected to outline an ambition to cut the time it takes to develop new vaccines by two-thirds to 100 days.

A Downing Street statement said developing a coronavirus vaccine in around 300 days is a “great and unprecedented global achievement”.

“By further reducing the time it takes to develop new vaccines against emerging diseases, we can potentially prevent the disastrous health, economic and social effects of this crisis,” the government said.

The Coalition for Innovations to Prepare for Epidemics first proposed this 100-day goal earlier this year.

“The development of viable coronavirus vaccines offers the tempting prospect of a return to normal, but we must not rest on our laurels,” Johnson said ahead of the meeting.

“As leaders of the G7 today we have to say never again,” he added, calling on the coalition of leaders to use “collective ingenuity” to ensure that “vaccines, treatments and tests are ready to fight future health threats”. “”

Johnson has asked UK Government Chief Scientific Advisor Patrick Vallance to work with international partners including the World Health Organization and CEPI, along with industry and science experts, to help the G-7 accelerate the development of vaccines, treatments and tests to advise.

At Friday’s session, Johnson will also confirm the UK will share the majority of all future excess coronavirus vaccine doses with Covax. This is a global initiative jointly led by WHO and CEPI, among others, and aims to provide low-income countries with fair access to coronavirus vaccines.

On Friday, the EU announced that it would double its contribution to Covax to 1 billion euros (1.2 billion US dollars), while Germany pledged a further 900 million euros for the initiative, according to a statement by the European Commission, the EU’s executive branch.

Unequal guidelines for Covid vaccines

A Lancet paper released late last month highlighted that the 2 billion doses of vaccine allocated to low-income countries under the Covax Accelerator Program in 2021 represented only 20% of the vaccine needs of the countries participating in the program.

The paper followed a warning from the World Health Organization’s top official that the world was on the verge of “catastrophic moral failure” due to unequal Covid vaccine policies.

Dr. Tedros Adhanom Ghebreyesus on Jan. 18 condemned what he called the “first-me” approach from high-income countries, saying it was self-destructive and endangered the world’s poorest and most vulnerable.

Almost all high-income countries have prioritized the distribution of vaccines to their own populations. The international aid group Medecins Sans Frontieres has described what we are seeing today in terms of global access to vaccines as “far from an image of justice”.

The meeting on Friday will be the first in the UK’s “G-7 Presidency” in 2021. It will also be President Joe Biden’s first major multilateral engagement.

Johnson had drawn up a five-point plan to prevent future pandemics at the United Nations General Assembly last year. This will be the focus of the UK G7 Presidency on Friday.

Categories
World News

Israel Secretly Agrees to Fund Vaccines for Syria as A part of Prisoner Swap

JERUSALEM – When a young Israeli woman was released from custody in Syria this week after being arrested for illegally entering Syria, the official story was that she benefited from a simple prisoner swap. In return for her freedom, the Israeli government announced that she had been exchanged for two Syrian shepherds captured by the Israelis.

But if this deal between two hostile states that have never shared diplomatic relations sounded too quick and easy, it was. In fact, Israel had secretly agreed to a far more controversial ransom: the funding of an unknown number of coronavirus vaccines for Syria, according to an official familiar with the content of the negotiations.

Under the deal, Israel will pay Russia, which it brokered, to send Russia-made Sputnik-V vaccines to President Bashar al-Assad’s regime of Syria, the official said. Israel has administered at least one vaccine to nearly half of its 9.2 million population, while Syria – now entering its eleventh year of civil war – has not yet started introducing the vaccine.

The Israeli government declined to comment on the vaccination aspect of the deal, while a state-controlled Syrian news agency, the Syrian Arab News Agency, denied that vaccines were part of the deal. When asked about the vaccines in a television interview on Saturday night, Israeli Prime Minister Benjamin Netanyahu escaped the question and said only that no Israeli vaccines would be sent to Syria.

“We brought the woman with us, I’m glad,” said Mr. Netanyahu. He thanked Russian President Vladimir V. Putin and said: “I will not add more.”

The agreement is a rare moment of unsettled cooperation between two states that have waged multiple wars and still contest the sovereignty of a stretch of land, the Golan Heights, which Israel conquered from Syria in 1967.

It also highlights how vaccines are increasingly a feature of international diplomacy. And it reflects enormous and growing inequality between rich states like Israel, which have made significant strides with coronavirus vaccines and may soon return to some sort of normalcy – and poor ones like Syria, which haven’t.

Among the Palestinians, news reports about the Israel-Syria agreement have increased frustration at the low number of vaccines Israel is providing to Palestinians in the Occupied Territories. Israel has only delivered a few thousand vaccines to the roughly 2.8 million Palestinians in the occupied West Bank, and last week the Israeli government briefly delayed the delivery of a first batch of vaccines to Gaza, where nearly two million people live.

Israel claims that the Oslo Accords release it from its responsibility to provide Palestinian health care. But human rights activists and Palestinians cite the fourth Geneva Convention, which obliges an occupying power to coordinate with local authorities to maintain public health in an occupied area.

Israeli officials have said they must vaccinate their own people before turning to the Palestinians. But the Syria deal sends a different message, said Khaled Elgindy, a researcher and former advisor to the Palestinian leadership.

Updated

Apr. 20, 2021, 9:30 a.m. ET

“Israel stands ready to provide vaccines to Syrians outside of their borders, but at the same time is not making them available to an enormous occupied population for which they are legally responsible,” Elgindy said. “That seems to be a message that they are deliberately trying to evade their legal responsibility for the well-being of this occupied population.”

Among the Israelis, the prisoner swap has raised concerns about how a civilian was able to cross the heavily police and strained border with Syria, undiscovered by the Israeli authorities.

The 23-year-old woman traveled to Syria near Mount Hermon on February 2 without being detected by Israeli or Syrian forces. Your name cannot currently be published by court order.

Israel learned she was missing until her friends told the police that she was missing. She only entered Syrian custody after a Syrian civilian who approached her realized she was Israeli and called the police.

Israel then asked Russia – a Syrian ally with a strong military presence in the country – to help mediate its release. Russia and Israel have coordinated in similar episodes in the past. In 2016, Russia helped broker the return of an Israeli tank that was seized by Syrian forces in Lebanon in 1982. In 2019, Moscow facilitated the return of the body of an Israeli soldier, Zachary Baumel, who was killed in the same clash.

The woman grew up in an ultra-Orthodox family in a settlement in the West Bank and is said to have tried in the past to illegally enter Israel’s Arab neighbors – once in Jordan and once in Gaza. On both occasions she was arrested, brought back, questioned and warned by Israeli forces.

Israeli negotiators tried to act quickly to avoid a recurrence of the crisis that followed the disappearance of Avera Mengistu in the Gaza Strip, a man with a history of mental illness who marched into the strip in 2014 and has since been detained by militant Hamas becomes a group that frequently increases the price of his release.

Mr. Netanyahu spoke directly to Mr. Putin twice, while Israeli National Security Advisor Meir Ben-Shabbat communicated with his Russian counterpart Nikolai Patrushev.

The Syrians initially requested the release of two Syrian residents of the Golan Heights imprisoned in Israel, but that agreement collapsed after it became clear that the two did not want to return to Syria.

Israel then offered to release the two shepherds, and at some point in negotiations the possibility of vaccines was raised.

The Israeli cabinet approved the terms of the deal on Tuesday, the day the 23-year-old was flown to Moscow. After further negotiations between Israeli and Russian officials, she was returned to Israel on Thursday.

In Moscow, officials had not offered confirmation of such an agreement by late Saturday, and the Russian news media only covered Israeli publications.

But the Russian government has been using its vaccine skillfully for months in diplomacy from Latin America to the Middle East. On Thursday, Putin’s special envoy for Syria, Alexander Lavrentiev, suggested in an interview with the Tass news agency that Russia would deliver its Sputnik-V vaccine to Syria.

Patrick Kingsley reported from Jerusalem, Ronen Bergman from Tel Aviv and Andrew E. Kramer from Moscow. Hwaida Saad reported from Beirut and Carol Sutherland from Moshav Ben Ami, Israel.

Categories
Health

Coronavirus Vaccines Are Reaching American Arms

President Biden is also pushing for faster vaccinations – a case he is expected to bring on Friday when he travels to Kalamazoo, Michigan, to visit the manufacturing facility of Pfizer, one of two manufacturers of federally approved vaccines.

Federal officials estimate that up to six million vaccine doses are still unnecessarily stowed away. The release could increase the number of doses used by more than 10 percent – significantly accelerating the pace of the country’s vaccination program at a time when speed is vital to saving lives, containing disease and fighting off more contagious variants of the virus could. To date, 56 million shots have been administered and only 12 percent of Americans have received one or more doses.

The idea of ​​cans lying in the refrigerator while millions of people are on waiting lists has deeply frustrated government officials. The problem has two roots.

First, when the federal vaccination program for long-term care facilities began late last year, the CDC relied on the number of beds, even though occupancy rates are the lowest in years. According to the American Health Care Association, a trading group, only 68 percent of beds in nursing homes and 78 percent of beds in assisted living are filled.

Then the CDC doubled that allocation to cover staff. While four-fifths of long-term care residents opted for a vaccination during the first month of the program, 63 percent of staff received no shots, the agency reported. Some of them have since been vaccinated, although it is not known exactly how many more.

Despite a lack of acceptance, the pharmacy chains that administer the program have continued to withdraw their allocations from the federal government. At one point in Virginia, Dr. Avula, if they had used less than one of the three cans they had on hand.

Clark Mercer, Virginia Governor Ralph Northam’s chief of staff, said of “good, corporate, risk-averse companies”, “If they can pull down, they will pull down.”

Categories
Health

India might play an essential position in producing vaccines

A medical professional holds Covid-19 vaccine Covaxin vial during the nationwide vaccination campaign in Jaipur, Rajasthan, India, Saturday, February 6, 2021.

Vishal Bhatnagar | NurPhoto | Getty Images

India could become the second largest Covid vaccine maker in the world, and analysts say the country has the capacity to manufacture for both its own people and other developing countries.

Most of the world’s vaccines historically came from India. Even before Covid-19, the South Asian country was producing up to 60% of the world’s vaccines – and at relatively low costs.

“India was a vaccine manufacturing center before the pandemic and should be a strategic partner in vaccinating against COVID-19 worldwide,” JPMorgan analysts wrote in a report last month.

Consultancy firm Deloitte predicts India will rank second after the US in terms of coronavirus vaccine production this year. PS Easwaran, partner at Deloitte India, said more than 3.5 billion Covid vaccines could be produced in the country in 2021, compared to around 4 billion in the US

In addition, companies in India are currently increasing production to meet demand.

“We are expanding our annual capacity to deliver 700 million doses of our intramuscular COVAXIN,” said Indian company Bharat Biotech, which worked with the Indian State Council for Medical Research to develop a Covid vaccine.

Covaxin was approved for emergency use in India, but was controversial due to criticism that the approval was not transparent enough and because not enough efficacy data was published.

India vaccines suitable for developing countries

Another vaccine – known in India as Covishield and jointly developed by AstraZeneca and the University of Oxford – has also been approved as an emergency in India. It is made locally by the Serum Institute of India (SII).

SII manufactures around 50 million cans of Covishield every month, according to Reuters, and plans to grow production to 100 million cans per month by March.

Other Indian companies have agreed to make vaccines for developers such as the Russian Direct Investment Fund and the US company Johnson & Johnson. To be clear, these vaccine candidates have not yet been approved for use.

“Even without successful vaccine development from our own pipelines, the available capacity offers the opportunity to work as a contract manufacturer with approved vaccine developers in order to meet the supply needs, particularly for India and other countries [emerging markets]”said the JPMorgan report.

With a proven track record on the scale that vaccines are made, India should be able to ramp up production to meet international demand as well.

Nissy Solomon

Center for Policy Research

India’s vaccines are likely to be more suitable for developing countries, said K Srinath Reddy, president of the Public Health Foundation of India.

Some of today’s leading vaccines, such as those from Pfizer-BioNTech and Moderna, use messenger RNA (mRNA) technology, which uses genetic material to trigger the body’s infection control process.

These vaccines require “stringent cold chain requirements” that will be difficult or even “out of the realm of possibility,” for most health systems, Reddy said.

Vaccines made in India are easier to transport and cheaper, putting the country in a better position than the US and Europe when it comes to meeting demand in developing countries, he added.

India’s “proven record”

India’s enormous manufacturing capacity also gives analysts confidence that the country can provide vaccines to other nations.

New Delhi has pledged to send vaccines to its neighboring countries and has already delivered 15.6 million doses to 17 countries, according to Reuters.

“India’s manufacturing capacity is sufficient to meet domestic demand,” said Nissy Solomon, senior research associate at the Center for Public Policy Research (CPPR).

“With a proven track record of the same scale as vaccines, India should be able to ramp up production to meet international demand as well,” she told CNBC.

Solomon added that the country is monitoring domestic needs before making decisions about exports.

For its part, Bharat Biotech said it was “fully prepared to meet the needs of India and global public health”.

Vaccine storage and distribution challenge

However, there will be challenges as the country attempts to meet vaccine demand in India and beyond.

Jefferies stock analyst Abhishek Sharma wrote in a note that vaccine adoption in India has been slow. Even assuming the speed of vaccination will increase, Sharma estimates that only 22% of India’s 1.38 billion people can be vaccinated in one year.

That is roughly the number of people India would like to vaccinate by July or August.

“The supply of vaccines is less of an issue than the storage, distribution and intake of vaccines,” said Solomon of CPPR.

“India is unable to store and distribute such large quantities to the masses,” she said, adding that the country should “strategically” choose vaccines that do not need to be stored in extreme temperatures.

I would say that [these challenges are] more like speed limiters slowing the program down than actual roadblocks where the program must be stopped.

K Srinath Reddy

Public Health Foundation of India

The vaccines India is currently manufacturing require normal refrigeration. However, the vaccines manufactured by Pfizer-BioNTech must be stored at extremely cold temperatures of minus 70 degrees Celsius, while those made by Moderna must be stored at minus 20 degrees Celsius (minus 4 degrees Fahrenheit).

The “real challenge” lies in the sheer number of people who need to be vaccinated, said Reddy of the Public Health Foundation of India.

“This is the first time an adult vaccination program has been carried out on such an unprecedented scale,” he told CNBC.

He said vaccination programs usually focus on vaccinating children and mothers, and the logistics network may not be prepared to handle vaccines for entire populations.

Reddy suggested using the existing food cold chain for vaccines, hoping this could be resolved.

“I would say that [these challenges are] more like speed limiters slowing down the program than actual roadblocks where the program has to be stopped, “he said.